What insurance policy changes affect code Q21.9?

There are 3 tracked policy changes affecting code Q21.9, including updates from Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code Q21.9?

Payers that have issued tracked updates for code Q21.9 include: Aetna.

How do I get notified when code Q21.9 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code Q21.9. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code Q21.9?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

PAYER POLICY CHANGES

Q21.9 Insurance Policy Changes

ICD-10 Q21.9 is officially defined as "Congenital malformation of cardiac septum, unspecified." code Q21.9 is referenced in 3 tracked payer policy changes from Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code Q21.9 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Aetna · Identified Oct 26, 2026Medium impact
Rebreathing of Inert Gas for Measurement of Cardiac Output and Validation of Intra-Cardiac Shunt (CPB 0714, reviewed 2026-10-20)
Aetna clinical policy bulletin 0714, last reviewed October 20, 2026, covers rebreathing of inert gas for measuring cardiac output and for validating intra-cardiac shunt. The policy considers three uses experimental, investigational or unproven because their effectiveness has not been established: measuring cardiac output, predicting survival in persons with pulmonary hypertension, and validating intra-cardiac shunt.
Aetna · Identified Aug 15, 2026Medium impact
Rebreathing of Inert Gas for Measurement of Cardiac Output and Validation of Intra-Cardiac Shunt (CPB 0714, reviewed 2025-11-25)
Rebreathing of inert gas for the measurement of cardiac output, for the prediction of survival in persons with pulmonary hypertension, and for the validation of intra-cardiac shunt is considered experimental, investigational, or unproven because the effectiveness of these approaches has not been established. The policy lists ICD-10 codes I27.0, I27.20 to I27.29 (pulmonary hypertension) and Q21.0 to Q21.9 (congenital malformations of cardiac septa, intra cardiac shunt) as not covered for the indications listed in the policy. The policy lists no specific CPT or HCPCS codes for measuring cardiac output with inert gas rebreathing.
Aetna · Identified Aug 13, 2026Medium impact
Palivizumab (Synagis) (CPB 0318, reviewed 2025-11-24)
Aetna considers palivizumab (Synagis) medically necessary for commercial medical plans for up to 5 doses per RSV season to prevent serious lower respiratory tract disease caused by RSV, when a member has a qualifying diagnosis such as prematurity, chronic lung disease of prematurity, hemodynamically significant congenital heart disease, cystic fibrosis or profound immunocompromise and the associated criteria are met. Palivizumab is excluded for members who have received nirsevimab-alip (Beyfortus) in the same RSV season. The American Academy of Pediatrics stated that in July 2025 it no longer routinely recommends using Synagis.

Watch Q21.9

Get one email when a payer policy names Q21.9, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Rebreathing of Inert Gas for Measurement of Cardiac Output and Validation of Intra-Cardiac Shunt (CPB 0714, reviewed 2026-10-20)

Rebreathing of Inert Gas for Measurement of Cardiac Output and Validation of Intra-Cardiac Shunt (CPB 0714, reviewed 2025-11-25)

Palivizumab (Synagis) (CPB 0318, reviewed 2025-11-24)

What insurance policy changes affect code Q21.9?

Which payers have updated policy for code Q21.9?

How do I get notified when code Q21.9 policy changes?

Why do payers change policies for code Q21.9?